Skip to Main content Skip to Navigation
Journal articles

Stability of Ophthalmic Atropine Solutions for Child Myopia Control

Abstract : Myopia is an ophthalmic condition affecting more than 1/5th of the world population, especially children. Low-dose atropine eyedrops have been shown to limit myopia evolution during treatment. However, there are currently no commercial industrial forms available and there is little data published concerning the stability of medications prepared by compounding pharmacies. The objective of this study was to evaluate the stability of two 0.1 mg/mL atropine formulations (with and without antimicrobiobial preservatives) for 6 months in two different low-density polyethylene (LDPE) multidose eyedroppers. Analyses used were the following: visual inspection, turbidity, chromaticity measurements, osmolality and pH measurements, atropine quantification by a stability-indicating liquid chromatography method, breakdown product research, and sterility assay. In an in-use study, atropine quantification was also performed on the drops emitted from the multidose eyedroppers. All tested parameters remained stable during the 6 months period, with atropine concentrations above 94.7% of initial concentration. A breakdown product (tropic acid) did increase slowly over time but remained well below usually admitted concentrations. Atropine concentrations remained stable during the in-use study. Both formulations of 0.1 mg/mL of atropine (with and without antimicrobial preservative) were proved to be physicochemically stable for 6 months at 25 °C when stored in LDPE bottles, with an identical microbial shelf-life.
Document type :
Journal articles
Complete list of metadata
Contributor : Stéphanie Bonnefoy Connect in order to contact the contributor
Submitted on : Thursday, February 11, 2021 - 4:36:10 PM
Last modification on : Saturday, June 25, 2022 - 9:32:20 AM

Links full text




Baptiste Berton, Philip Chennell, Mouloud Yessaad, Yassine Bouattour, Mireille Jouannet, et al.. Stability of Ophthalmic Atropine Solutions for Child Myopia Control. Pharmaceutics, MDPI, 2020, 12 (8), pp.781. ⟨10.3390/pharmaceutics12080781⟩. ⟨hal-03139107⟩



Record views